DLC Asia Limited (HKG:8210)

Ligand Pharmaceuticals Income Statement

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Total Interest Expense	0.12	0.13	0.07	0.15	0.09
Net Interest Income	-0.12	-0.13	-0.07	-0.15	-0.09
Brokerage Commission	46.82	54.87	56.94	39.7	53.99
Other Revenue	1.69	1.43	0.19	-	0.01
Revenue	48.4	56.16	57.06	39.55	53.91
Revenue Growth (YoY)	-13.82%	-1.57%	44.25%	-26.63%	-1.11%
Salaries & Employee Benefits	30.39	35.19	36.53	28.8	39.33
Cost of Services Provided	1.6	1.9	1.4	-	1.6
Other Operating Expenses	14.72	15.54	15.72	13.81	15.5
Total Operating Expenses	48.18	54.08	53.77	45.18	59.17
Operating Income	0.22	2.08	3.28	-5.62	-5.26
Currency Exchange Gains	-	-	-0.05	-	0.13
EBT Excluding Unusual Items	0.22	2.08	3.24	-5.62	-5.13
Asset Writedown	-	-	-	-3.38	-
Other Unusual Items	-	-	0.5	-	1.49
Pretax Income	0.22	2.08	3.74	-9	-3.63
Income Tax Expense	0.08	0.22	-0.17	-0.18	-0.09
Net Income	0.13	1.86	3.91	-8.82	-3.55
Net Income to Common	0.13	1.86	3.91	-8.82	-3.55
Net Income Growth	-92.88%	-52.58%	-	-	-
Shares Outstanding (Basic)	800	800	800	790	744
Shares Outstanding (Diluted)	800	800	800	790	744
Shares Change (YoY)	-	-	1.26%	6.18%	4.18%
EPS (Basic)	0.00	0.00	0.00	-0.01	-0.00
EPS (Diluted)	0.00	0.00	0.00	-0.01	-0.00
EPS Growth	-92.88%	-52.60%	-	-	-
Free Cash Flow	2.59	3.12	2.74	-8.67	8.67
Free Cash Flow Per Share	0.00	0.00	0.00	-0.01	0.01
Operating Margin	0.45%	3.70%	5.76%	-14.22%	-9.75%
Profit Margin	0.27%	3.30%	6.86%	-22.30%	-6.58%
Free Cash Flow Margin	5.36%	5.55%	4.79%	-21.92%	16.08%
Effective Tax Rate	38.89%	10.77%	-	-	-
Revenue as Reported	48.52	56.29	57.63	39.7	55.62

Source: S&P Global Market Intelligence. Capital Markets template. Financial Sources.